Methyclothiazide is a synthetic thiazide diuretic used in pharmaceutical formulations for the management of conditions associated with excess fluid retention and elevated blood pressure. It promotes the excretion of sodium and water through the kidneys and belongs to the benzothiadiazine/thiazide class of diuretics.
Methyclothiazide acts primarily by inhibiting the sodium-chloride cotransporter (NCC) in the distal convoluted tubule of the nephron. This reduces sodium and chloride reabsorption and increases urinary excretion of water and electrolytes.
Methyclothiazide is supplied as an Active Pharmaceutical Ingredient (API) for qualified pharmaceutical manufacturing, formulation development, analytical testing and research applications.
Methyclothiazide inhibits the Na⁺/Cl⁻ cotransporter in the distal convoluted tubule of the kidney. This decreases sodium and chloride reabsorption and increases the urinary excretion of sodium and water.
Thiazide diuretics can also reduce urinary calcium excretion and produce a sustained reduction in blood pressure with continued use.
Methyclothiazide is associated with pharmaceutical applications including:
The approved indication and dosage depend on the specific pharmaceutical formulation and applicable regulatory requirements.
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 1.0% |
| Melting Point | Approximately 230–233 °C |